Natural Product (NP) Details
| General Information of the NP (ID: NP6740) | |||||
|---|---|---|---|---|---|
| Name |
Capsaicin
|
||||
| Synonyms |
Capsaicin (transdermal patch formulation, neuropathic pain)
Click to Show/Hide
|
||||
| Species Origin | Capsicum annuum ... | Click to Show/Hide | |||
| Capsicum annuum | |||||
| Disease | Neuropathic pain [ICD-11: 8E43] | Approved | [1] | ||
| Structure |
|
Click to Download Mol2D MOL |
|||
| ADMET Property |
Absporption
Caco-2 Permeability
-5.273
MDCK Permeability
-4.841
PAMPA
- - -
HIA
- - -
Distribution
VDss
-0.315
PPB
97.8%
BBB
- - -
Metabolism
CYP1A2 inhibitor
+++
CYP1A2 substrate
- - -
CYP2C19 inhibitor
++
CYP2C19 substrate
+++
CYP2C9 inhibitor
+++
CYP2C9 substrate
+++
CYP2D6 inhibitor
- - -
CYP2D6 substrate
+++
CYP3A4 inhibitor
+++
CYP3A4 substrate
+++
CYP2B6 inhibitor
+++
CYP2B6 substrate
+++
CYP2C8 inhibitor
+++
HLM Stability
+++
Excretion
CLplasma
7.094
T1/2
0.374
Toxicity
DILI
- -
Rat Oral Acute Toxicity
- - -
FDAMDD
- -
Respiratory
+
Human Hepatotoxicity
++
Ototoxicity
- -
Drug-induced Nephrotoxicity
-
Drug-induced Neurotoxicity
-
Hematotoxicity
- -
Genotoxicity
+
Tips: 1. For the classification endpoints, the prediction probability values are transformed into six symbols: 0-0.1 (- - -), 0.1-0.3 (- -), 0.3-0.5 (-), 0.5-0.7 (+), 0.7-0.9 (++), and 0.9-1.0 (+++).
2. Additionally, the corresponding relationships of the three labels are as follows: excellent; medium; poor.
Click to Show/Hide
|
||||
| Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | |||||
| Formula |
C18H27NO3
|
||||
| PubChem CID | |||||
| Canonical SMILES |
CC(C)C=CCCCCC(=O)NCC1=CC(=C(C=C1)O)OC
|
||||
| InChI |
1S/C18H27NO3/c1-14(2)8-6-4-5-7-9-18(21)19-13-15-10-11-16(20)17(12-15)22-3/h6,8,10-12,14,20H,4-5,7,9,13H2,1-3H3,(H,19,21)/b8-6+
|
||||
| InChIKey |
YKPUWZUDDOIDPM-SOFGYWHQSA-N
|
||||
| CAS Number |
CAS 404-86-4
|
||||
| Herb ID | |||||
| ETMC ID | |||||
| SymMap ID | |||||
| TCMSP ID | |||||
| TTD Drug ID | |||||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP | ||||||
| 3,3'-diindolylmethane | Breast cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [2] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Up-regulation | Expression | BAK | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Expression | BAX | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | BBC3 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | BID | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | CDK4 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | CDK6 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | CDKN1A | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | FAS | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | IFI27 | Molecule Info | |||
| Up-regulation | Expression | p105 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | TP53 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | HCT 116 | CVCL_0291 | Colon carcinoma | Homo sapiens | ||
| SW480 | CVCL_0546 | Colon adenocarcinoma | Homo sapiens | |||
| LoVo | CVCL_0399 | Colon adenocarcinoma | Homo sapiens | |||
| Caco-2 | CVCL_0025 | Colon adenocarcinoma | Homo sapiens | |||
| HT-29 | CVCL_0320 | Colon adenocarcinoma | Homo sapiens | |||
| Experimental
Result(s) |
Capsaicin and DIM work synergistically to inhibit cell proliferation and induce apoptosis in colorectal cancer through modulating transcriptional activity of NF-kappaB, p53, and target genes associated with apoptosis. | |||||
| Erlotinib | Lung cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
| Augmenting Drug Sensitivity | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [3] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Down-regulation | Phosphorylation | AKT1 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | ERCC1 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | A-549 | CVCL_0023 | Lung adenocarcinoma | Homo sapiens | ||
| NCI-H1975 | CVCL_1511 | Lung adenocarcinoma | Homo sapiens | |||
| Experimental
Result(s) |
Capsaicin enhances erlotinib-induced cytotoxicity via AKT inactivation and excision repair cross-complementary 1 (ERCC1) down-regulation in human lung cancer cells. | |||||
| TNF-related apoptosis inducing ligand | Lung cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
| Augmenting Drug Sensitivity | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [4] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Down-regulation | Expression | BIRC5 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | CCNB1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | POLD1 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | TRAIL-R2 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | U-87MG ATCC | CVCL_0022 | Glioblastoma | Homo sapiens | ||
| U-343MG | CVCL_S471 | Glioblastoma | Homo sapiens | |||
| T98 | CVCL_B368 | Glioblastoma | Homo sapiens | |||
| SNU-444 | CVCL_5060 | Glioblastoma | Homo sapiens | |||
| U-251MG | CVCL_0021 | Astrocytoma | Homo sapiens | |||
| Experimental
Result(s) |
Capsaicin sensitizes malignant glioma cells to TRAIL-mediated apoptosis via DR5 upregulation and survivin downregulation. | |||||
| Sorafenib | Renal cell carcinoma | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [5] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Up-regulation | Expression | BAX | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | CASP3 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | EGFR | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | PARP1 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | LM3 | CVCL_D269 | Malignant neoplasms | Mus musculus | ||
| Hep 3B2.1-7 | CVCL_0326 | Childhood hepatocellular carcinoma | Homo sapiens | |||
| Huh-7 | CVCL_0336 | Adult hepatocellular carcinoma | Homo sapiens | |||
| In-vivo Model | Five-week-old BALB/C nude mice received a subcutaneous injection of 1*107 LM3 cells suspended in 100 uL sterile PBS into the right flank. | |||||
| Experimental
Result(s) |
Capsaicin and sorafenib combination treatment exerts synergistic anti-hepatocellular carcinoma activity by suppressing EGFR and PI3K/Akt/mTOR signaling. | |||||
| 5-fluorouracil | Solid tumour/cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [6] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Up-regulation | Phosphorylation | AKT1 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | ATG3 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | BECN1 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | MAP1LC3A | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Phosphorylation | S6K1 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | QBC939 | CVCL_6942 | Cholangiocarcinoma | Homo sapiens | ||
| SK-ChA-1 | CVCL_6952 | Cholangiocarcinoma | Homo sapiens | |||
| Mz-ChA-1 | CVCL_6932 | Gallbladder carcinoma | Homo sapiens | |||
| Experimental
Result(s) |
Capsaicin enhances 5FU sensitivity of cholangiocarcinoma through the inhibition of 5FU-induced autophagy by activating the PI3K/AKT/mTOR pathway. | |||||
| β. A List of Drug(s) Whose Resistance can be Reversed by This NP | ||||||
| Cisplatin | Bladder cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
| Reversing Drug Resistance | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [7] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Down-regulation | Expression | AURKA | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Phosphorylation | NFKBIA | Molecule Info |
Pathway MAP
|
||
| Biological
Regulation |
Induction | Cell cycle arrest in G1/S phase | ||||
| In-vitro Model | SNU-1 | CVCL_0099 | Gastric adenocarcinoma | Homo sapiens | ||
| SNU-5 | CVCL_0078 | Gastric adenocarcinoma | Homo sapiens | |||
| SNU-16 | CVCL_0076 | Gastric adenocarcinoma | Homo sapiens | |||
| SNU-601 | CVCL_0101 | Gastric adenocarcinoma | Homo sapiens | |||
| SNU-638 | CVCL_0102 | Gastric adenocarcinoma | Homo sapiens | |||
| SNU-668 | CVCL_5081 | Gastric adenocarcinoma | Homo sapiens | |||
| Experimental
Result(s) |
Capsaicin induces apoptosis of cisplatin-resistant stomach cancer cells by causing degradation of cisplatin-inducible Aurora-A protein. | |||||
| Target and Pathway | ||||
|---|---|---|---|---|
| Target(s) | Transient receptor cation channel V1 (TRPV1) | Molecule Info | [8] | |
| KEGG Pathway | Neuroactive ligand-receptor interaction | Click to Show/Hide | ||
| 2 | Inflammatory mediator regulation of TRP channels | |||
| NetPath Pathway | IL2 Signaling Pathway | Click to Show/Hide | ||
| Pathway Interaction Database | Trk receptor signaling mediated by the MAPK pathway | Click to Show/Hide | ||
| 2 | Trk receptor signaling mediated by PI3K and PLC-gamma | |||
| Reactome | TRP channels | Click to Show/Hide | ||
